Keyphrases
Fracture Prevention
74%
Osteoporotic Fractures
71%
Comorbidity
71%
Surgical Centre
66%
Relative Survival Analysis
66%
Osteoporotic Patients
66%
Intact Parathyroid Hormone (iPTH)
66%
Register Study
66%
Long-run Risk
66%
Subsequent Fracture
66%
Hormone Treatment
66%
Health Economic Analysis
66%
National Register
66%
Long-term Benefit
66%
Older People
66%
National Cohort Study
66%
Fracture Risk
66%
Bilateral Exploration
40%
Area of Residence
33%
Chronic Disease
29%
Bisphosphonates
28%
Preoperative Localization
26%
Societal Costs
22%
Productivity Costs
22%
General Practice
22%
Study of Osteoporotic Fracture
22%
Cost-of-illness Study
22%
Direct Costs
22%
Lower Leg Injury
20%
Humerus Fracture
16%
Primary Hip
16%
Wrist Fracture
16%
Remote Rural
16%
Comorbidity Index
14%
Anti-osteoporosis
14%
Solitary Adenoma
13%
Bilateral Neck Exploration
13%
Payer Perspective
9%
Public Payer
9%
Drug Consumption
9%
Pharmaceutical Treatment
9%
Comparative Cost-effectiveness
7%
Incident Fractures
7%
Cluster Risks
7%
Discriminative Performance
7%
Prevention Strategies
7%
Denmark
7%
Cox Regression
7%
Fracture Patient
7%
Early Disease
7%
Medicine and Dentistry
Health Care Cost
100%
Hip Fracture
88%
Fragility Fracture
88%
Cohort Analysis
66%
Primary Hyperparathyroidism
66%
Heart Failure
66%
Hormone Therapy
66%
Cohort Effect
66%
Humerus
66%
Hip
66%
Parathyroid Hormone
66%
Case-Control Study
66%
Marital Status
44%
Odds Ratio
44%
Bisphosphonate
28%
Public Health
26%
Osteoporosis
26%
Logistic Regression Analysis
22%
Wrist Fracture
22%
Humerus Fracture
22%
Cost-Effectiveness Analysis
19%
Quality Adjusted Life Year
19%
Health Care
16%
Forearm Fracture
16%
Computer Assisted Tomography
13%
Adenoma
13%
Neck
13%
Imaging Technique
13%
Parathyroid Adenoma
13%
Methoxy Isobutyl Isonitrile Technetium Tc 99m
13%
Four Dimensional Computed Tomography
13%
Parathyroid Gland
13%
Diseases
9%
Blood Pressure
9%
Nurse
9%
Remote Patient Monitoring
9%
New York Heart Association Class
9%
Care Group
9%
Primary Health Care
9%
Nursing and Health Professions
Cost Effectiveness Analysis
85%
Health Care Cost
76%
Fragility Fracture
71%
Anticoagulant Agent
66%
Patient-Reported Outcome
66%
Hormonal Therapy
66%
Economic Evaluation
66%
Warfarin
66%
Parathyroid Hormone
66%
Cohort Analysis
66%
Heart Failure
66%
Quality Adjusted Life Year
44%
General Practice
33%
Osteoarthritis
33%
Orthopedic Surgery
33%
Bisphosphonic Acid Derivative
28%
Cost Utility Analysis
26%
Atrial Fibrillation
25%
Hip Osteoarthritis
22%
Knee Osteoarthritis
22%
Cost Control
17%
Incremental Cost-Effectiveness Ratio
16%
Anticoagulant Therapy
16%
Drug Therapy
13%
Orthopedic Surgeon
11%
General Practitioner
11%
Primary Medical Care
9%
Drug Use
9%
Care Group
9%
New York Heart Association Class
9%
Disease
9%
Telemonitoring
9%
Base
8%